$KPRX SEC Filings

Filed On	Filing
29 Oct 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure Date of report (Date of earliest event reported): October 23, 2026
17 Sep 2026	SCHEDULE 13G
17 Sep 2026	Form 4: Lane Keith J., EVP, Clinical and Regulatory Granted 55,000 Stock Option (right to buy)
17 Sep 2026	Form 3: Lane Keith J., EVP, Clinical and Regulatory No securities owned
08 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure Kiara Pharmaceuticals, Inc. (the "Company'') is pleased to offer you employment with a start date of September 1, 2026 (the "Start Date"). Your role shall be to serve as Executive Vice President, Head of Clinical Development and Regulato...
19 Aug 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G/A
10 Aug 2026	SCHEDULE 13G
07 Aug 2026	10-Q
07 Aug 2026	8-K: Results of Operations and Financial Condition
02 Jul 2026	Form 4: Tosca Melissa, CFO Gave up 911 shares to cover exercise price or tax ($2.42K)
02 Jul 2026	Form 4: Strem Brian M., Director Gave up 1,869 shares to cover exercise price or tax ($4.97K)
18 Jun 2026	8-K: Regulation FD Disclosure
12 Jun 2026	Form 4: Stengone Carmine N., Director Granted 25,000 Stock Option (right to buy)
12 Jun 2026	Form 4: Shapiro Aron, Director Granted 25,000 Stock Option (right to buy)
12 Jun 2026	Form 4: Parsons Erin, Director Granted 25,000 Stock Option (right to buy)
12 Jun 2026	Form 4: Hollander David, Director Granted 25,000 Stock Option (right to buy)
12 Jun 2026	Form 4: Walters-Hoffert Lisa, Director Granted 25,000 Stock Option (right to buy)
12 Jun 2026	Form 4: Tyle Praveen, Director Granted 40,000 Stock Option (right to buy)

Comments